Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peritoneal papillary carcinoma.

S B Lele1, M S Piver, J Matharu

  • 1Department of Gynecologic Oncology, Roswell Park Memorial Institute Buffalo, New York 14263.

Gynecologic Oncology
|October 1, 1988
PubMed
Summary

Peritoneal papillary cancer is rare, often widespread, but responds well to chemotherapy. Cisplatin-based regimens show a 65% response rate in these patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.

International journal of cancer·2017
Same author

Short message service (SMS) texting as a method of communication during on call: prevalence and experience of medical staff in a large acute NHS Trust in the UK.

The British journal of oral & maxillofacial surgery·2016
Same author

Contemporary management of benign parotid tumours - the increasing evidence for extracapsular dissection.

Oral diseases·2016
Same author

Innervation of the lower third of the sternocleidomastoid muscle by the ansa cervicalis through the C1 descendens hypoglossal branch: a previously unreported anatomical variant.

The British journal of oral & maxillofacial surgery·2015
Same author

Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer.

European journal of gynaecological oncology·2012
Same author

The 21st century role of Piver type II hysterectomy in FIGO stage IA, IB cervical cancer: a personal perspective.

European journal of gynaecological oncology·2008

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Pathology

Background:

  • Peritoneal papillary cancer is a rare malignancy.
  • It is often diagnosed at advanced stages with widespread abdominal involvement.

Purpose of the Study:

  • To review the clinical characteristics and treatment outcomes of peritoneal papillary cancer.
  • To evaluate the efficacy of chemotherapy in patients with this diagnosis.

Main Methods:

  • Retrospective review of 325 patients diagnosed with ovarian carcinoma, peritoneal cancer, or malignant mesothelioma between 1977 and 1986.
  • Identification of 23 patients with peritoneal papillary cancer.
  • Analysis of treatment responses to various combination chemotherapeutic agents, particularly cisplatin-based regimens.

Main Results:

  • 23 cases (7%) of peritoneal papillary cancer were identified.
  • Most patients (21/23) presented with widespread abdominal disease.
  • First-line chemotherapy achieved an overall response rate exceeding 65%.
  • Cisplatin combination chemotherapy in 20 patients resulted in a 65% response rate.

Conclusions:

  • Peritoneal papillary cancer is an uncommon but aggressive malignancy.
  • Chemotherapy, especially cisplatin-based combinations, demonstrates significant efficacy in managing this disease.
  • Early diagnosis and prompt treatment are crucial for improving patient outcomes.

Related Experiment Videos